Vor, Janssen partner on combination immunotherapy for leukemia

By The Science Advisory Board staff writers

July 8, 2021 -- Vor Biopharma is collaborating with Janssen Biotech to develop engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer.

Under the collaboration, Vor will investigate the combination of Vor's "invisible" engineered hematopoietic stem cell transplant platform and Janssen's bispecific antibodies into a treatment solution for acute myeloid leukemia.

"We believe this unique combination will leverage each technology's strengths, while protecting patients against off-target effects of these powerful immunotherapies," said Tirtha Chakraborty, PhD, chief scientific officer of Vor.

As part of the agreement, each company will retain all rights and ownership to their respective programs and platforms. Additional financial details were not disclosed.

Vor, Abound Bio to develop multitargeted CAR T therapies
Vor Biopharma has entered into a multiyear strategic collaboration and license agreement with Abound Bio to research both single- and multitargeted chimeric...

Copyright © 2021 scienceboard.net


Conferences
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
International Society for Pharmaceutical Engineering Annual Meeting
October 30 - November 2
Orlando, Florida United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter